Vivus Company Profile (NASDAQ:VVUS)

Analyst Ratings

Consensus Ratings for Vivus (NASDAQ:VVUS) (?)
Ratings Breakdown: 4 Hold Rating(s)
Consensus Rating:Hold (Score: 2.00)
Consensus Price Target: $1.90 (63.79% upside)

Analysts' Ratings History for Vivus (NASDAQ:VVUS)
Show:
DateFirmActionRatingPrice TargetActions
5/4/2016JPMorgan Chase & Co.Reiterated RatingHoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/4/2016WallachBeth CapitalDowngradeBuy -> HoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/10/2016Needham & Company LLCReiterated RatingHoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/29/2016Royal Bank Of CanadaDowngradeOutperform -> Sector Perform$4.00 -> $1.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/6/2014Bank of America Corp.Reiterated RatingUnderperform$4.00 -> $3.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
9/4/2014Credit Suisse Group AGInitiated CoverageNeutralView Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/23/2014 forward)

Earnings

Earnings History for Vivus (NASDAQ:VVUS)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
7/28/2016        
5/3/2016Q116($0.21)($0.12)$17.97 million$15.32 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/9/2016Q4($0.12)($0.12)$22.90 million$15.34 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/4/2015Q315($0.17)($0.15)$20.24 million$24.90 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
7/30/2015Q215($0.23)($0.19)$18.76 million$23.00 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/5/2015Q115($0.22)($0.15)$21.80 million$32.20 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/24/2015Q414($0.25)($0.25)$20.00 million$21.70 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/5/2014Q314($0.25)($0.10)$21.90 million$33.90 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/7/2014Q214($0.28)($0.25)$17.90 million$21.90 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/5/2014Q114($0.37)($0.15)$11.40 million$36.70 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/24/2014Q413($0.40)($0.17)$28.20 million$44.06 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/5/2013Q313($0.38)($0.48)$21.78 million$27.38 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/6/2013Q2 2013($0.44)($0.55)$12.76 million$5.53 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/8/2013Q1 2013($0.51)($0.53)$5.22 million$4.10 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/25/2013Q4 2012($0.44)($0.56)$3.09 million$1.97 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/6/2012Q312($0.34)($0.40)$0.35 million$0.04 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/7/2012($0.23)($0.24)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/7/2012($0.13)($0.20)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/28/2012($0.12)($0.14)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/7/2011($0.12)($0.10)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/1/2011($0.13)($0.20)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/2/2011($0.15)($0.12)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/28/2011($0.22)($0.23)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Vivus (NASDAQ:VVUS)
No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Vivus (NASDAQ:VVUS)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Vivus (NASDAQ:VVUS)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
7/1/2016Santosh T VargheseVPSell366$1.21$442.86View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/7/2016Santosh T VargheseInsiderSell329$1.65$542.85View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/1/2016North Tide Capital, LlcMajor ShareholderBuy2,160$1.40$3,024.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/31/2016North Tide Capital, LlcMajor ShareholderBuy383,300$1.29$494,457.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/28/2016North Tide Capital, LlcMajor ShareholderBuy202,000$1.12$226,240.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/16/2016North Tide Capital, LlcMajor ShareholderBuy500,000$1.21$605,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/1/2016John L SlebirSVPSell2,973$3.04$9,037.92View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/8/2015North Tide Capital, LlcMajor ShareholderBuy500,000$3.12$1,560,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/6/2015North Tide Capital, LlcMajor ShareholderBuy476,800$3.04$1,449,472.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/2/2015North Tide Capital, LlcMajor ShareholderBuy523,200$2.90$1,517,280.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/11/2014Seth H.Z. FischerCEOBuy3,080$6.07$18,695.60View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/11/2013Alexander DennerDirectorBuy566,844$8.59$4,869,189.96View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/5/2013Timothy E MorrisCFOSell10,654$11.95$127,315.30View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/4/2013Michael J AstrueDirectorBuy10,000$11.96$119,600.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/27/2013Jon C BiroInsiderBuy2,000$12.85$25,700.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/29/2013Ernest MarioDirectorBuy15,000$14.68$220,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/20/2012Ernest MarioDirectorBuy5,000$20.75$103,750.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/10/2012Ernest MarioDirectorBuy20,000$21.74$434,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Vivus (NASDAQ:VVUS)
DateHeadline
07/22/16 06:59 PMVIVUS Announces Favorable Markman Ruling in Qsymia® Patent Litigation
07/22/16 06:59 PMVIVUS (VVUS) Announces Receipt of Favorable Markman Decision in Qsymia Patent Spat
07/22/16 10:06 AMVIVUS (VVUS) Announces Receipt of Favorable Markman Decision in Qsymia Patent Spat - StreetInsider.com
07/22/16 06:36 AMVIVUS holding its ground against would-be generic makers of Qsymia -
07/22/16 05:03 AMVIVUS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits -
07/21/16 10:02 AMVivus Begins Q3 With Underwhelming Qsymia Sales - Seeking Alpha
07/21/16 10:02 AMVIVUS Inc. (NASDAQ:VVUS) Fundamental Star Rating Report - CML News
07/19/16 07:22 PMVIVUS, Inc. (NASDAQ:VVUS): Sell-Side Ratings and Company Earnings Glance - Engelwood Daily
07/19/16 07:22 PMTahithromos LLC Decreased Stake in Vivus INC (NASDAQ:VVUS) by $4.57 Million as Shares Rose - Press Telegraph
07/16/16 10:22 AMVIVUS Inc Realized Volatility Hits Extreme Level - CML News
07/15/16 06:12 PMCrowd Rating and Earnings Recap for VIVUS, Inc. (NASDAQ:VVUS) - Telanagana Press
07/15/16 06:12 PMShares Experiencing a Downtrend: VIVUS Inc. (NASDAQ:VVUS) - TGP
07/15/16 06:12 PMVIVUS, Inc. (NASDAQ:VVUS) Current Analyst Ratings - Fiscal Standard
07/14/16 07:26 PMVIVUS, Inc. (NASDAQ:VVUS) Wall Street Analyst Recommendation Outlook - Telanagana Press
07/13/16 07:31 PMHow Many VIVUS, Inc. (NASDAQ:VVUS)'s Analysts Are Bearish? - Consumer Eagle
07/12/16 11:07 AMVIVUS Inc Stock Momentum at Critical Inflection Point - CML News
07/12/16 11:07 AMTrading Performance and Target Watch for VIVUS, Inc. (NASDAQ:VVUS) - Press Telegraph
07/12/16 11:07 AMVIVUS, Inc. (NASDAQ:VVUS) Earnings Concentration and Analyst Target Watch - Engelwood Daily
07/08/16 10:00 AMWall Street Ratings and Target Price Views on VIVUS, Inc. (NASDAQ:VVUS) - Telanagana Press
07/07/16 07:16 PMOption Market: VIVUS Inc. Risk Hits An Extreme High - CML News
07/07/16 07:16 PMVIVUS, Inc. (NASDAQ:VVUS) VP - Medical & Reg Affairs Santosh Varghese, Sold $443 in Stock - Engelwood Daily
07/07/16 07:16 PMVIVUS, Inc. (NASDAQ:VVUS) Stock Update: Check on Ratings and Target Price - Telanagana Press
07/06/16 07:42 PMWere Analysts Bearish VIVUS, Inc. (NASDAQ:VVUS) This Week? - Engelwood Daily
07/06/16 07:42 PMInsiders Increasing Positions in: VIVUS Inc. (NASDAQ:VVUS) - Press Telegraph
07/06/16 05:47 AMStock Rating Watch and Earnings Insight for VIVUS, Inc. (NASDAQ:VVUS) - Press Telegraph
07/05/16 06:47 PMVIVUS Inc. (VVUS) Jumps 8.93% on July 04 - Equities.com
07/05/16 05:34 AMVIVUS, Inc. (NASDAQ:VVUS) Broker Price Targets For The Coming Week - Fiscal Standard
07/02/16 09:44 AMSell-Side Recommendation & Price Target Projections on VIVUS, Inc. (NASDAQ:VVUS) - Telanagana Press
07/02/16 09:44 AMTracking Stock Volatility for: VIVUS Inc. (NASDAQ:VVUS) - Engelwood Daily
07/01/16 09:51 AMArena (ARNA) to Cut 73% Workforce, Shifts Focus to Pipeline
06/30/16 07:24 PMVIVUS (VVUS), Auxilium to Extend STENDRA License Agreement Through August 31 - StreetInsider.com
06/30/16 07:24 PMVIVUS, Inc. (NASDAQ:VVUS) Company Rating and Target Watch - Telanagana Press
06/30/16 03:41 PMVIVUS to Extend Return Date of STENDRA Commercial Rights - [at noodls] - VIVUS and Auxilium Agree to Extend the STENDRA(R) (avanafil) License Agreement Through August 31, 2016 MOUNTAIN VIEW, CA -- (Marketwired) -- 06/30/16 -- VIVUS, Inc.(NASDAQ: VVUS)(the 'Company'), a biopharmaceutical ...
06/30/16 03:22 PMVIVUS INC Files SEC form 8-K, Termination of a Material Definitive Agreement, Regulation FD Disclosure, Financial Sta -
06/30/16 03:18 PM4:18 pm Vivus extends termination date of the license agreement with Endo International (ENDP) subsidiary Auxilium Pharma for the US & Canadian commercial rights to Stendra -
06/30/16 11:45 AMETF’s with exposure to VIVUS, Inc. : June 30, 2016 -
06/29/16 07:05 PMVIVUS, Inc. (NASDAQ:VVUS) Updated Price Targets - FTSE News
06/27/16 06:57 PMTwo Stocks within Analysts Review: Pfizer, Inc. (NYSE:PFE) , VIVUS, Inc. (NASDAQ:VVUS) - Street Updates
06/27/16 06:57 PMVIVUS, Inc. (NASDAQ:VVUS) & Williams Companies (NYSE:WMB) Stocks in the News - Wall Street 24
06/27/16 05:54 AMNext Weeks Broker Price Targets For VIVUS, Inc. (NASDAQ:VVUS) - Fiscal Standard
06/26/16 05:53 AMShare Volatility Check for: VIVUS Inc. (NASDAQ:VVUS) - Press Telegraph
06/26/16 05:53 AMRecently Issued Stock Ratings For VIVUS, Inc. (NASDAQ:VVUS) - Fiscal Standard
06/22/16 05:57 AMVIVUS (VVUS) Notified of ANDA Filing for Generic Avanafil Tabs
06/21/16 03:07 PMVIVUS INC Files SEC form 8-K, Other Events -
06/20/16 08:32 AMVIVUS, Inc. (NASDAQ:VVUS) Analyst Price Targets For The Coming Week - Fiscal Standard
06/17/16 04:37 PMETF’s with exposure to VIVUS, Inc. : June 17, 2016 -
06/15/16 07:03 PMEarnings Expectation Watch List: Mitsubishi UFJ Financial Group, Inc. (NYSE:MTU), VIVUS Inc. (NASDAQ:VVUS) - Beacon Chronicle
06/13/16 10:08 AMEye Catching Stocks: VIVUS Inc. (NASDAQ:VVUS), QUALCOMM, Inc. (NASDAQ:QCOM), Southwestern Energy ... - KC Register
06/13/16 10:08 AMVivus - Qsymia Scripts Continue Slow Path - Seeking Alpha
06/06/16 11:24 AMImmunomedics Inc. (NASDAQ:IMMU) Stock Plunges: VIVUS Inc. (NASDAQ:VVUS), Arena Pharmaceuticals, Inc ... - KC Register

Social

About Vivus

Vivus logoVIVUS, Inc. is a biopharmaceutical company. The Company operates in the development and commercialization of therapeutic products segment. It provides over two therapies approved by the Food and Drug Association (FDA), which include Qsymia (phentermine and topiramate extended-release) for chronic weight management and STENDRA (avanafil) for erectile dysfunction (ED). The Company has completed the Phase II studies of Qsymia for the indication of Obstructive Sleep Apnea (OSA) and diabetes. Its Qsymia is available in over 40,000 certified retail pharmacies across the country. Its STENDRA is also approved by the European Commission (EC), under the name, SPEDRA, for the treatment of ED in the Europe. The United States Food and Drug Association approved a Supplemental New Drug Application (sNDA) for STENDRA. STENDRA is indicated to be taken approximately 15 minutes before sexual activity.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Pharmaceuticals
  • Exchange: NASDAQ
  • Symbol: VVUS
  • CUSIP: 92855110
Key Metrics:
  • Previous Close: $1.16
  • 50 Day Moving Average: $1.17
  • 200 Day Moving Average: $1.22
  • P/E Ratio: N/A
  • P/E Growth: -2.09
  • Market Cap: $120.74M
  • Beta: 1.16
  • Current Year EPS Consensus Estimate: $-1.02 EPS
  • Next Year EPS Consensus Estimate: $-0.73 EPS
Additional Links:
Vivus (NASDAQ:VVUS) Chart for Saturday, July, 23, 2016